ARCELLX
Arcellx is a clinical-stage biotechnology company reimagining cell therapy by engineering innovative immunotherapies for patients with cancer and other incurable diseases. Arcellx believes that cell therapies are one of the forward pillars of medicine and Arcellx’s mission is to advance humanity by developing cell therapies that are safer, more effective, and more broadly accessible. Arcellx’s lead product candidate, CART-ddBCMA, is being developed for the treatment of relapsed or refractory... multiple myeloma (r/r MM) in an ongoing Phase 1 study. CART-ddBCMA has been granted Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy designations by the U.S. Food and Drug Administration. Arcellx is also advancing its dosable and controllable CAR-T therapy, ARC-SparX, into the clinic through two programs: ACLX-001 in r/r MM and ACLX-002 in relapsed or refractory acute myeloid leukemia.
ARCELLX
Industry:
Biopharma Biotechnology Health Care Life Science Pharmaceutical
Founded:
2015-01-01
Address:
Gaithersburg, Maryland, United States
Country:
United States
Website Url:
http://www.arcellx.com
Total Employee:
101+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
622 M USD
Technology used in webpage:
Domain Not Resolving Google Maps Amazon HSTS IPv6 U.S. Server Location Amazon Virginia Region GoDaddy SSL Comcast Q4Web Hosting
Similar Organizations
Antheia
A synthetic biology company for next generation plant-inspired medicines
Athelas
Athelas develops technology to monitor chronically ill patients in their homes.
Avidity Biosciences
Avidity Biosciences is a biotechnology company that develops oligonucleotide-based therapies for its patients.
Capital Rx
Capital Rx is a healthtech platform that provides pharmacy benefit management solutions.
Capsule
Capsule is a healthcare technology business rebuilding the pharmacy from the inside out
Cleo
Cleo is a benefits platform that provides personalized guidance for working families.
Resilience
Resilience provides end-to-end biopharmaceutical manufacturing and development solutions.
Trevena
Trevena is a clinical stage biopharmaceutical company discovering and developing G-protein coupled receptors (GPCR) biased ligands.
Twist Bioscience
Twist Bioscience is a synthetic DNA production for specialty chemical compounds and drug development.
Zealand Pharma
Zealand Pharma is a biotechnology company that offers scientific expertise in turning peptides into medicines.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Kite Pharma
Kite Pharma investment in Post-IPO Equity - Arcellx
Kite Pharma
Kite Pharma investment in Post-IPO Equity - Arcellx
Suvretta Capital Management
Suvretta Capital Management investment in Series C - Arcellx
Terra Magnum Capital Partners (""""TMCP"""")""
Terra Magnum Capital Partners (""""TMCP"""")"" investment in Series C - Arcellx
LG Technology Ventures
LG Technology Ventures investment in Series C - Arcellx
Novo Holdings
Novo Holdings investment in Series C - Arcellx
CaaS Capital Management
CaaS Capital Management investment in Series C - Arcellx
Adage Capital Management
Adage Capital Management investment in Series C - Arcellx
Soleus Capital
Soleus Capital investment in Series C - Arcellx
Clough Capital Partners
Clough Capital Partners investment in Series C - Arcellx
Key Employee Changes
| Date | New article |
|---|---|
| 2022-05-23 | Arcellx Names Michelle Gilson as New CFO |
Official Site Inspections
http://www.arcellx.com Semrush global rank: 2.04 M Semrush visits lastest month: 10.16 K
- Host name: 141.193.213.20
- IP address: 141.193.213.20
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Arcellx"
Arcellx Cell Therapies for Cancer and Autoimmune Diseases
Arcellx Presents Pre-Clinical Data for ACLX-002, a Novel CD123-targeted Universal CAR-T Cell Therapy for Relapsed or Refractory Acute Myeloid Leukemia at the American Association for …See details»
Arcellx - Crunchbase Company Profile & Funding
Arcellx is a clinical-stage biotechnology company reimagining cell therapy by engineering innovative immunotherapies for patients with cancer and other incurable diseases. Arcellx believes that cell therapies are one of the forward …See details»
Investor Relations - Arcellx
Aug 8, 2024 Arcellx, Inc. (NASDAQ: ACLX) is a clinical-stage biotechnology company reimagining cell therapy by engineering innovative immunotherapies for patients with cancer …See details»
Arcellx Appoints Rami Elghandour as Chairman and Chief …
GAITHERSBURG, Md., Jan. 26, 2021 (GLOBE NEWSWIRE) – – Arcellx, a privately held clinical-stage biopharmaceutical company developing adaptive and controllable cell therapies, today …See details»
Kite and Arcellx Announce Strategic Collaboration to Co-develop …
Dec 9, 2022 To deliver cell therapy globally, and at scale, it requires a highly coordinated, vertically integrated organization from R&D to commercialization to manufacturing, dedicated …See details»
Arcellx Appoints Rami Elghandour as Chairman and Chief …
Jan 26, 2021 He is a recipient of the Bill Campbell award by Watermark, a leading women's organization, for his influence, impact, and advocacy in promoting women and women's …See details»
Arcellx, Inc. (ACLX) Stock Price, News, Quote & History - Yahoo …
Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead …See details»
A Brief History of Arcellx – CBM
2 days ago [cbm_blg_rlnkng]Founded in 2018, Arcellx is a revolutionary biopharmaceutical company that is transforming the landscape of cell therapy. Specializing in the development of adaptive and precisely controlled cell …See details»
Arcellx Announces Executive Appointments
Arcellx Announces Executive Appointments. GAITHERSBURG, Md., April 19, 2021 (GLOBE NEWSWIRE) – – Arcellx, ... “The additions of Chris and Neeraj emphasize our commitment to …See details»
Arcellx, Inc. (ACLX) Stock Price, News, Quote & History
Find the latest Arcellx, Inc. (ACLX) stock quote, history, news and other vital information to help you with your stock trading and investing.See details»
Arcellx Provides Fourth Quarter and Year-End 2023 Financial …
Feb 28, 2024 Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other …See details»
Events & Presentations - Arcellx
Oct 9, 2024 At Arcellx, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are …See details»
Arcellx Company Profile, Stock Price, News, Rankings | Fortune
Best Small and Medium Workplaces in Biotechnology and Pharmaceuticals 2023 Employees say: "Arcellx is a people-centered culture. Management holds themselves to living our values and …See details»
Information and Support for Patients, About Cell Therapy - Arcellx
Here at Arcellx, we’re focused on reimagining CAR-T cell therapy, which stands for chimeric antigen receptor (CAR) T cell (T) therapy. Other types of cell therapy include: Tumor-infiltrating …See details»
Arcellx, Inc. Reports Q3 2024 Earnings Highlights - Nasdaq
5 days ago Arcellx holds a strong cash position with $161.85 million in cash and equivalents, and $514.84 million in marketable securities, providing a solid financial foundation. Moving …See details»
News - Arcellx
Feb 29, 2024 At Arcellx, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are …See details»
Our Pipeline, Focus Areas, and Clinical Trials - Arcellx
Arcellx intends to develop multiple assets and novel technology to combat a variety of solid tumor indications while leveraging the strengths of each of our existing ddCAR and ARC-SparX …See details»
Arcellx: Navigating The CAR T-Cell Revolution (NASDAQ:ACLX)
Jan 30, 2024 Arcellx has an EV/Sales TTM of 61.23 and an EV/Sales FWD of 42.78, both of which are above the sector median, implying high market assumptions for the company's …See details»